Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies
Andrea Leonardi, Elisabeth M Messmer, Marc Labetoulle, Mourad Amrane, Jean-Sébastien Garrigue, Dahlia Ismail, Maite Sainz-de-la-Maza, Francisco C Figueiredo, Christophe Baudouin, Andrea Leonardi, Elisabeth M Messmer, Marc Labetoulle, Mourad Amrane, Jean-Sébastien Garrigue, Dahlia Ismail, Maite Sainz-de-la-Maza, Francisco C Figueiredo, Christophe Baudouin
Abstract
Background/aim: To assess the treatment effect of 0.1% ciclosporin A cationic emulsion (CsA CE) versus vehicle on signs/symptoms of dry eye disease (DED) in various subgroups (moderate-to-severe DED/severe DED/Sjögren's syndrome (SS)/SS with severe DED).
Methods: Pooled data were analysed from two similar phase III studies: SICCANOVE (moderate-to-severe DED) and SANSIKA (severe DED with severe keratitis). In both studies, patients aged ≥18 years received CsA CE 0.1% (n=395) or vehicle (n=339) once daily for 6 months. A composite responder efficacy endpoint (corneal fluorescein staining-Ocular Surface Disease Index (CFS-OSDI) at month 6) was used to evaluate the efficacy of CsA CE in alleviating signs/symptoms of DED (response defined as improvement of ≥2 grades in CFS and ≥30% in OSDI (baseline to month 6)). Human leucocyte antigen-DR (HLA-DR) conjunctival expression was used as a biomarker of ocular surface inflammation.
Results: CsA CE-treated patients were significantly more likely to be CFS-OSDI responders than vehicle-treated patients in the overall (OR 1.66, 95% CI 1.11 to 2.50; P=0.015), severe DED (1.80, 1.04 to 3.19; P=0.038) and SS with severe DED (3.37, 1.20 to 11.19; P=0.030) populations. The difference was not significant for CsA CE versus vehicle for the overall Sjögren's population (OR 1.77, CI 0.89 to 3.66; P=0.109). CsA CE also significantly reduced median HLA-DR expression versus vehicle at 6 months (P=0.002).
Conclusion: Pooled phase III data indicate CsA CE produced significant improvement in signs/symptoms versus vehicle in patients with moderate-to-severe DED (especially in those with severe keratitis), including patients with SS with severe DED.
Keywords: ocular surface; tears; treatment medical.
Conflict of interest statement
Competing interests: AL is a consultant for, or has received a research grant from, Allergan, Alcon, MediVis, Santen, SIFI and Théa and was an investigator in the SICCANOVE and SANSIKA studies. EMM is a consultant for, or has received speaker honoraria from, Alcon Pharma GmbH, Dompé, Pharm-Allergan GmbH, Santen GmbH, Shire, Théa Pharma GmbH, TRB Chemedica AG, Ursapharm and VISUfarma and was an investigator in the SICCANOVE study. ML is a consultant for, or has received a research grant from, Alcon, Allergan, Bausch & Lomb, Dompé, Santen and Théa and was an investigator in the SICCANOVE and SANSIKA studies. MA is an employee of Santen SAS. J-SG is an employee of Santen SAS. DI is an employee of Santen SAS. MS-d-l-M is a consultant for Santen and was an investigator in the SICCANOVE and SANSIKA studies. FCF is a consultant for, or has received a research grant from, Allergan, Théa and Santen and was an investigator in the SICCANOVE and SANSIKA studies. CB is a consultant for, or has received a research grant from, Alcon, Allergan, Santen and Théa and was a clinical investigator in the SICCANOVE and SANSIKA studies.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Figures
References
- Craig JP, Nichols KK, Akpek EK, et al. . TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276–83. 10.1016/j.jtos.2017.05.008
- Stapleton F, Alves M, Bunya VY, et al. . TFOS DEWS II epidemiology report. Ocul Surf 2017;15:334–65. 10.1016/j.jtos.2017.05.003
- Labetoulle M, Rolando M, Baudouin C, et al. . Patients' perception of DED and its relation with time to diagnosis and quality of life: an international and multilingual survey. Br J Ophthalmol 2017;101:1100–5. 10.1136/bjophthalmol-2016-309193
- Baudouin C, Aragona P, Messmer EM, et al. . Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf 2013;11:246–58. 10.1016/j.jtos.2013.07.003
- Baudouin C, Irkeç M, Messmer EM, et al. . ODISSEY European Consensus Group Members. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol 2017;96:111–9.
- Baudouin C. The vicious circle in dry eye syndrome: a mechanistic approach. J Fr Ophtalmol 2007;3:239–46.
- Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol 2009;3:405–12. 10.2147/OPTH.S5555
- Bron AJ, de Paiva CS, Chauhan SK, et al. . TFOS DEWS II pathophysiology report. Ocul Surf 2017;15:438–510. 10.1016/j.jtos.2017.05.011
- Labbé A, Baudouin C, Ismail D, et al. . Pan-European survey of the topical ocular use of cyclosporine A. J Fr Ophtalmol 2017;40:187–95. 10.1016/j.jfo.2016.12.004
- Lallemand F, Felt-Baeyens O, Besseghir K, et al. . Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003;56:307–18. 10.1016/S0939-6411(03)00138-3
- Lallemand F, Daull P, Benita S, et al. . Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv 2012;2012:1–16. 10.1155/2012/604204
- Lallemand F, Schmitt M, Bourges JL, et al. . Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm 2017;117:14–28. 10.1016/j.ejpb.2017.03.006
- Daull P, Lallemand F, Philips B, et al. . Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea 2013;32:345–54. 10.1097/ICO.0b013e31825e83f4
- Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol 2014;66:531–41. 10.1111/jphp.12075
- Leonardi A, Van Setten G, Amrane M, et al. . Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 2016;26:287–96. 10.5301/ejo.5000779
- Baudouin C, Figueiredo FC, Messmer EM, et al. . A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol 2017;27:520–30. 10.5301/EJO.5000952
- Baudouin C, de la Maza MS, Amrane M, et al. . One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol 2017;27:678–85.
- Amrane M, Creuzot-Garcher C, Robert PY, et al. . Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease—a randomised comparative study. J Fr Ophtalmol 2014;37:589–98. 10.1016/j.jfo.2014.05.001
- Lemp MA, Baudouin C, Amrane M, et al. . Poor correlation between dry eye disease (DED) signs and symptoms in a phase III randomized clinical trial [abstract]. Invest Ophthalmol Vis Sci 2011;52:3821.
- Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf 2009;7:199–211. 10.1016/S1542-0124(12)70187-8
- Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23:762–70. 10.1097/01.ico.0000133997.07144.9e
- Felson DT, Anderson JJ, Boers M, et al. . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35. 10.1002/art.1780380602
- Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate-to-severe dry eye: results of a physician survey. Eye Contact Lens 2010;36:33–8. 10.1097/ICL.0b013e3181c739ad
- Foulks GN. Treatment of dry eye disease by the non-ophthalmologist. Rheum Dis Clin North Am 2008;34:987–1000. 10.1016/j.rdc.2008.08.008
- Foulks GN, Forstot SL, Donshik PC, et al. . Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf 2015;13:118–32. 10.1016/j.jtos.2014.12.001
- Brignole-Baudouin F, Riancho L, Ismail D, et al. . Correlation between the inflammatory marker HLA-DR and signs and symptoms in moderate to severe dry eye disease. Invest Ophthalmol Vis Sci 2017;58:2438–48. 10.1167/iovs.15-16555
- Brignole F, Pisella PJ, De Saint Jean M, et al. . Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001;42:90–5.
- Sall K, Stevenson OD, Mundorf TK, et al. . Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631–9.
- Baudouin C, Aragona P, Van Setten G, et al. . Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol 2014;98:1168–76. 10.1136/bjophthalmol-2013-304619
- van Setten G, Labetoulle M, Garrigue JS, et al. . A new diagnostic algorithm in severe dry eye disease patients participating in a clinical trial with 1 mg/mL ciclosporin cationic emulsion Proceedings of the 2015 annual meeting of the american academy of ophthalmology. Las Vegas, NV, Nov 13–17, 2015 Poster PO049.
- van Setten G, Labetoulle M, Baudouin C, et al. . Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmol 2016;94:499–506. 10.1111/aos.12985
Source: PubMed